Development and evaluation of dry powder inhalation system of terbutaline sulphate for better management of asthma

International Journal of Advances in Pharmaceutical Sciences

Volumn 1, Issue 2, 2010, Pages 133-141

  Singh, Deepak J Singh ^a   Parmar, Jayesh J ^a   Hegde, Darshana D ^a   Lohade, Atul A ^d   Soni, Pritamsingh ^b   Samad, Abdul ^c   Menon, Mala D ^a  

^a BOMBAY COLLEGE OF PHARMACY   (India)

^b Board of Radiat/Isotope Technology   (India)

^c BOMBAY VETERINARY COLLEGE   (India)

^d NONE

Author keywords

Dry powder inhalation; Microspheres; Pulmonary delivery; Turbutaline sulphate

Indexed keywords

CHITOSAN; MICROSPHERE; TERBUTALINE SULFATE;

ARTICLE; ASTHMA; CROSS LINKING; DENSITY; DRUG INDICATION; DRUG RELEASE; DRY POWDER; EMULSION; GELATION; LUNG FLUID; MOISTURE; PARTICLE SIZE; PHYSICAL CHEMISTRY; POWDER INHALER; SCANNING ELECTRON MICROSCOPE;

EID: 79952011367     PISSN: None     EISSN: 09761055     Source Type: Journal    
DOI: 10.5138/ijaps.2010.0976.1055.01015     Document Type: Article

References (23)

1. Courrier H.M.; Butz N.; and Vandamme T.F. Pulmonary drug delivery systems: Recent developments and prospects. Crit. Rev. Therpeut. Drug Carrier Systems 2002, 19, 425-498.
2. Groneberg D.A.; Witt C.; Wagner U.; Chung K. F. and Fischer A. Fundamentals of pulmonary drug delivery. Respir. Med. 2003, 97, 382-387.
3. Zeng X. M.; Martin G. P.; and Marriott C. The controlled delivery of drugs to the lung. Int. J. Pharm. 1995;124: 149-164.
4. Witek T. J. The Fate of Inhaled Drugs: The pharmacokinetics and pharmacodynamics of drugs administered by aerosol. Respir. Care 2000, 45, 826-830.
5. Clark A. R. Pulmonary Delivery Technology: Recent Advances and Potential for the New Millennium. In: Anthony J. Hickey editor. Pharmaceutical Inhalation Aerosol Technology. 2nd ed. New York: Marcel Dekker Inc, 2004. 563-84.
6. Byron P. R. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J. Pharm. Sci. 1986, 75, 433-438.
7. Shenfield G. M.; Evans M. E. and Paterson J. W. Absorption of drugs by the lung. Br. J. Clin. Pharm. 1976, 3,1218-1223.
8. Adjei A. and Gupta P. Dry-powder inhalation aerosols. In A. L. Adjei A. L., P. K. Gupta (eds.), Inhalation Delivery of Therapeutic Peptides and Proteins. M. Dekker, New York. 1997, 625-665.
9. Weers J. Dispersible powders for inhalation applications. Innov. Pharm. Technol. 2000, 1,111-116.
10. Duddu S.; Sisk S. and Walter Y. Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere powder. Pharm. Res. 2002, 19, 689-695.
11. Smolensky M. H.; D'Alonzo G. E.; Kunkel G. and Barnes P. J. Day-night patterns in bronchial patency and dyspnoea: Basis for one daily and unequally divided twice daily dosing schedules. Chronobio. Int. 1987, 4,303-307.
12. Moebus K.; Siepmann J. and Bodmeier R. Alginate-poloxamer microparticles for controlled drug delivery to mucosal tissue. Europ. J. Pharma. And Biopharm.2009, 72 (1), 42-53.
13. Martinac A.; Filipovic-Grcic J.; Voinovich D.; Perissutti B. and Franceschinis E. Development and bioadhesive properties of chitosan-ethylcellulose microspheres for nasal delivery, Int. J. Pharm. 2005, 291, 69-77.
14. Mi F.; Wong T.; Shyu S. and Chang S. Chitosan microspheres: modification of polymeric anti--physical properties of spray dried microspheres to control the release of antibiotic drug. J. Appl. Polm. Sci. 1999, 71, 747-759.
15. Berthold K.; Cremer J. and Kreuter J. Preparation and characterization of chitosan microspheres as drug carrier for prednisolone sodium phosphate as model for anti-inflammatory drugs, J. Control. Release. 1996, 39, 17-25.
16. Lamprecht A.; Helena R.; Ulrich S. and Claus-Michael L. Biodegradable microparticles as a two-drug controlled release formulation: a potential treatment of inflammatory bowel disease. J. Control. Release. 2000, 69, 445-454.
17. Peniche C.; Waldo A.; Hazel P. and Niuris A. Chitosan: An attractive biocompatible polymer for microencapsulation, Macromol. Biosci. 2003, 3, 511-520.
18. Anal A.; Willem F. and Carmen R. Ionotropic cross-linked chitosan microspheres for controlled release of ampicillin, Int. J. Pharm. 2006, 312, 166-173.
19. Lim L.; Wan L. and Thai P. Chitosan microspheres prepared by emulsification and ionotropic gelation. Drug Dev. Ind. Pharm. 1997, 23, 981-985.
20. Nishioka Y.; Kyotani S.; Okamura M.; Miyazaki M.; Okazaki K.; Ohnishi S.; Yamamoto Y. and Ito K. Release characteristics of cisplatin chitosan microspheres and effect of containing chitin. Chem. Pharm. Bull. 1990, 38, 2871-2873.
21. Staniforth J. Improvement in dry powder inhaler performance: Surface passivation effects. 1996, Proc. Drug Delivery Lungs (London) VII, 86-89.
22. Lucas P.; Anderson K.; Potter U. and Staniforth J. Enhancement of small particle size dry powder aerosol formulations using an ultra low density additive. Pharm. Res. 1999,16, 1643-1647.
23. Louey M.; Razia S. and Stewart P. Influence of physicochemical carrier properties on the in vitro aerosol deposition from interactive mixtures. Int. J. Pharm. 2003, 252 (1-2), 87-98.